Arcutis Biotherapeutics (ARQT) EBIT (2021 - 2025)
Historic EBIT for Arcutis Biotherapeutics (ARQT) over the last 5 years, with Q3 2025 value amounting to $8.5 million.
- Arcutis Biotherapeutics' EBIT rose 12182.46% to $8.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$38.2 million, marking a year-over-year increase of 7897.81%. This contributed to the annual value of -$128.4 million for FY2024, which is 4674.56% up from last year.
- According to the latest figures from Q3 2025, Arcutis Biotherapeutics' EBIT is $8.5 million, which was up 12182.46% from -$14.6 million recorded in Q2 2025.
- In the past 5 years, Arcutis Biotherapeutics' EBIT registered a high of $8.5 million during Q3 2025, and its lowest value of -$104.7 million during Q3 2022.
- In the last 5 years, Arcutis Biotherapeutics' EBIT had a median value of -$50.1 million in 2024 and averaged -$47.8 million.
- In the last 5 years, Arcutis Biotherapeutics' EBIT crashed by 8351.73% in 2022 and then surged by 12182.46% in 2025.
- Quarter analysis of 5 years shows Arcutis Biotherapeutics' EBIT stood at -$71.3 million in 2021, then rose by 4.01% to -$68.4 million in 2022, then rose by 10.6% to -$61.2 million in 2023, then surged by 87.52% to -$7.6 million in 2024, then skyrocketed by 211.71% to $8.5 million in 2025.
- Its last three reported values are $8.5 million in Q3 2025, -$14.6 million for Q2 2025, and -$24.5 million during Q1 2025.